Anteris Technologies GlobalAVR -5.00%23 EPS without NRI is $-2.22 as of Mar. 2026. GuruFocus rates AVR with a GF Score™ of 23/100. The stock has 7 warning signs investors should review. Among 667 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 65.07% on this metric.
Anteris Technologies Global's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.28.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.22.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -2.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -9.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Anteris Technologies Global's EPS without NRI or its related term are showing as below:
AVR'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34.9 Med: 7.9 Max: 31.7
Current: -2.3
During the past 13 years, Anteris Technologies Global's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 31.70% per year. The lowest was -34.90% per year. And the median was 7.90% per year.
AVR's 3-Year EPS without NRI Growth Rate is ranked worse than 65.07% of 667
companies
in the Medical Devices & Instruments industry
Industry Median: 8.2
vs AVR: -2.30
Anteris Technologies Global (NAS:AVR) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Anteris Technologies Global EPS without NRI Related Terms
Anteris Technologies Global EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVR vs INMD, QDEL, SSII: EPS without NRI Comparison
For the Medical Devices subindustry, Anteris Technologies Global's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's PE Ratio without NRI falls into.
Anteris Technologies Global EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global (AVR) has a EPS without NRI of $-2.22 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #434 out of 667 companies in the Medical Devices & Instruments industry, placing it in the top 65.1%.
Is Anteris Technologies Global's EPS without NRI too high?
Anteris Technologies Global's current EPS without NRI is $-2.22. Based on the distribution chart, Anteris Technologies Global ranks #434 out of 667 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Anteris Technologies Global has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's EPS without NRI compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #434 out of 667 companies for EPS without NRI. This places Anteris Technologies Global in the lower half of its industry. The industry median EPS without NRI is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.20, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current EPS without NRI is $-2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (AVR) has a current EPS without NRI of $-2.22. The current EPS without NRI is $-2.22. Anteris Technologies Global's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Anteris Technologies Global (AVR), the current EPS without NRI is $-2.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
23GF Score
Get the complete analysis for AVR
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVR has been successfully added to your 
